TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02650661

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online health management program
Description: Web-based health management program designed according to SMASH strategy, which includes (i) Assessment, (ii) Acceptance, (iii) Preparation for change, (iv) Commitment, (v) Planning, (vi) Promoting environment, (vii) Execution, (viii) Feedback and Maintenance, and (ix) Core perspectives, for 6 months.~The program consists of four areas: self-assessment, self-planning, self-learning, and self-monitoring. The learning session includes SMASH strategies and 10 Rules for Highly Effective Health Behavior.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online health management program
Description: Web-based health management program designed according to SMASH strategy, which includes (i) Assessment, (ii) Acceptance, (iii) Preparation for change, (iv) Commitment, (v) Planning, (vi) Promoting environment, (vii) Execution, (viii) Feedback and Maintenance, and (ix) Core perspectives, for 6 months.~The program consists of four areas: self-assessment, self-planning, self-learning, and self-monitoring. The learning session includes SMASH strategies and 10 Rules for Highly Effective Health Behavior.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health coaching
Description: Personalized tele-coaching for 6 months by health coaches who were trained by the Smart Management and Coaching for Health (SMACH) program

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Workshop
Description: Total three sessions are to be held at 3-, 5-, and 7-month after the initiation of the enrollment. Each session includes 30-minute health education, 1-hour health management strategy workshop, and 30-minute team coaching.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard health educational booklet
Description: Standard health educational booklets about 10 Rules for Highly Effective Health Behavior that are organized according to the Trans-theoretical Model (TTM).~Booklets are provided at 0-, 2-, and 4-month after the enrollment.
Study: NCT01628822

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active relaxation
Description: The length of follow-up will be 12 weeks.Patients will be seen once every seven days by a relaxation therapist for 5 weeks (6 sessions) and will be followed by the center physician investigator regarding drug therapy

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients are been asked to relax alone in a quiet room. They are coming every 7 days for 5 weeks (6 sessions) and will be followed by the investigator regarding drug therapy
Study: NCT02806206

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A single dose of a placebo pill will be given to each study participant just before the ingestion of the capsule endoscopy pill.
Study: NCT02679755

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: 125 mg/d capsules orally for 3 out of 4 weeks in repeated cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: 2.5 mg/d tablets orally on a continuous regimen
Study: NCT04158466

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kalifilcon A Daily Disposable Contact Lenses
Description: Contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Biotrue ONEday Daily Disposable Contact Lenses
Description: Contact lens
Study: NCT02996838

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQ-B3234
Description: TQ-B3234 p.o. qd
Study: NCT00965562

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluoxetine
Description: Fluoxetine 20 mg per day for 4 menstrual cycles. For the fifth menstrual cycle, all women will receive calcium. Women on Fluoxetine will continue taking it in addition to 1200mg of calcium.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium
Description: 1200 mg of calcium to be taken for 5 menstrual cycles.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: For 5 cycles, women will receive placebo. At the end of the fourth cycle, all women will receive 1200 mg of calcium in addition to the placebo medication.
Study: NCT03015428

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: psychoeducation
Description: Providing knowledge and skills development in family caregivers of people with dementia, through a structured psychoeducational programme
Study: NCT03553056

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NZ Step Away app
Description: Access to 10 modules of the app (namely: drinkers profile, goal setting, rewards, cravings, strategies, support, reminders, high risk times, moods, activities)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Modified NZ Step Away app
Description: Access to 2 modules of the app (namely: drinkers profile and goals setting)
Study: NCT03448562

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CPVI
Description: ablate around the pulmonary vein orifice
Study: NCT04755608

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Intensity Exercises with Blood Flow Restriction
Description: In the exercise protocol, people exercised resistance between 20% and 30% of 1 MaxRepetition with free weight. In addition, blood flow was restricted in 70% of the arterial occlusion pressure of the individual with the help of a cuff during exercise.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High Intensity Resistant Exercise
Description: People included in the study did resistance exercise with free weight at 70-80% of 1 MT.
Study: NCT04014062

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: INTP5
Description: INTP5: A proposed pegfilgrastim biosimilar to US Neulasta.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: INTP5
Description: INTP5: A proposed pegfilgrastim biosimilar to US Neulasta.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: US Neulasta
Description: US Neulasta: FDA-approved pegfilgrastim innovator product.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: US Neulasta
Description: US Neulasta: FDA-approved pegfilgrastim innovator product.
Study: NCT02328248

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biological patch
Description: Use biological patch as opposed to plastic patch to repair hiatal hernia laparoscopically
Study: NCT01635595

Intervention type: PROCEDURE
Intervention: Subtotal esophagectomy and gastric pull up
Description: Subtotal esophagectomy and gastric pull up and radical thoracic (2,3,4R,7,8,9)and abdominal (15,16,17,18,19,20) lymphadenectomy

Intervention type: PROCEDURE
Intervention: Subtotal esophagectomy at the azygos vein, total gastrectomy
Description: Subtotal esophagectomy at the azygos vein, total gastrectomy and esophagojejunostomy and radical thoracic (2,3,4R,7,8,9) abdominal (15,16,17,18,19,20) lymphadenectomy.
Study: NCT02610777

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azacitidine
Description: Azacitidine intravenous or subcutaneous formulation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Azacitidine intravenous or subcutaneous formulation.
Study: NCT03448562

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CPVI
Description: ablate around the pulmonary vein orifice
Study: NCT01452204

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Pulsed Electromagnetical Field and Exercise
Description: G1: MT, three times per week lasting 30' each session. G2: placebo MT, 3 X week lasting 30'each session. After 3 weeks of application of MT, will begin a program of exercises.
Study: NCT03448562

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: STABLE-SR
Description: homogenization of the low voltage zones and elimination of the complex electrograms from the transitional zones during sinus rhythm
Study: NCT01452204

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulsed Electromagnetical Field and Exercise
Description: G1: MT, three times per week lasting 30' each session. G2: placebo MT, 3 X week lasting 30'each session. After 3 weeks of application of MT, will begin a program of exercises.
Study: NCT02232958

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hyperbaric Oxygen Treatment
Description: Patients are placed in a special chamber in which the pressure is gradually increased up to the desired pressure with 100% Oxygen and the patient is kept at that pressure for one hour. Then the Oxygen flow is slowly reduced until the patient has been returned to one atmosphere of pressure.
Study: NCT02195882

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Exercise program of the scapular muscle stabilizers
Study: NCT00913874

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Divalproex Sodium 500 mg DR Tablets (Sandoz Inc., USA)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Depakote 500 mg DR Tablets (Abbott Laboratories, USA)
Study: NCT03728166

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Electronic alert
Description: On-screen electronic alert that notifies the provider about the increased risk for VTE after discharge and indication for thromboprophylaxis will be issued 48 hours after admission. This first on-screen electronic alert will provide the clinician with the opportunity to consider extended-duration, post-discharge thromboprophylaxis and start any required processes for prior authorization or medication coverage. The provider then will be given on-screen options to either order thromboprophylaxis (betrixaban or low-molecular weight heparin for 35 days) from a Extended-Duration VTE Prevention order template, follow a link to evidence-based practice guidelines, or defer prescribing extended-duration, post-discharge thromboprophylaxis.
Study: NCT01904266

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: GA + paravertebral block
Description: 20 cc ropivacaine 0.2% will be administered in an ultrasound-guided paravertebral block

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: GA + sham block
Description: Injection of 1 cc saline subcutaneously
Study: NCT01874821

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dynasplint
Description: Dynamic splinting utilizes the protocols of Low-Load Prolonged Stretch (LLPS) with calibrated adjustable tension to increase Total End Range Time (TERT)to reduce contracture. The Dynasplint or Experimental group will add this therapy to their standard of care regimen

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care
Description: The current Standard of Care for treating this condition includes corticosteroid injections and physical therapy.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: The current Standard of Care for treating this condition includes corticosteroid injections and physical therapy.
Study: NCT00994123

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MM-121
Description: MM-121 (SAR256212) = intravenous solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MM-121
Description: MM-121 (SAR256212) = intravenous solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: erlotinib = daily oral tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erlotinib
Description: erlotinib = daily oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: erlotinib = daily oral tablet
Study: NCT03172910

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciraparantag
Description: Ciraparantag (administered over 10 minutes)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciraparantag
Description: Ciraparantag (administered over 10 minutes)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciraparantag
Description: Ciraparantag (administered over 10 minutes)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciraparantag
Description: Ciraparantag (administered over 10 minutes)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Description: Rivaroxaban 20 mg given once per day (QD) in the morning

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Description: Rivaroxaban 20 mg given once per day (QD) in the morning

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Description: Rivaroxaban 20 mg given once per day (QD) in the morning

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Description: Rivaroxaban 20 mg given once per day (QD) in the morning

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rivaroxaban
Description: Rivaroxaban 20 mg given once per day (QD) in the morning
Study: NCT03377803

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: VP-102 - Cantharidin, Topical Film Forming Solution
Description: VP-102, a single-use drug device combination product containing (cantharidin) topical solution, 0.7% (w/v). Up to 4 applications of VP-102 will be administered to Molluscum lesions at 21-day intervals.
Study: NCT03869541

Intervention type: OTHER
Intervention: Mobilization
Description: Physical rehabilitation
Study: NCT00472368

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LBH589
Study: NCT03377803

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo -Topical Film Forming Solution without VP-102
Description: Placebo a single-use drug device combination product containing only the vehicle. Up to 4 applications of Placebo will be administered to Molluscum lesions at 21-day intervals.
Study: NCT02610777

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pevonedistat
Description: Pevonedistat intravenous infusion.
Study: NCT02871635

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 695501
Study: NCT04773366

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone+Cytarabine+vincristine
Description: Group 1 initial treatment (W1\~W6). Prednisone 40mg/m2×4w, taper 2w; Vincristine 1.5mg/m2 iv d1 of w1,2,3,4,5,6; Cytarabine 100mg/m2 iv/IH d1-4 q2w (w1,3,5)
Study: NCT02871635

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BI 695501

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HUMIRA
Study: NCT01460134

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDX-1127
Description: Patients will initially receive a single dose of CDX-1127, followed by a 28-day observation period and a Multi-Dose Phase (one cycle of 4 weekly doses of CDX-1127). All patients with stable disease who do not experience a DLT or start alternate anti-cancer treatments may then be eligible for a Retreatment Phase (up to 4 additional cycles). Patients with confirmed partial response or complete response will be followed for response duration and may be eligible for additional cycles of treatment at the time of relapse/progression.~The dose of CDX-1127 given for the Dose Escalation phase will depend on the cohort each patient is assigned to, and will range between 0.1 and 10.0 mg/kg of CDX-1127.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDX-1127
Description: Patients will initially receive a single dose of CDX-1127, followed by a 28-day observation period and a Multi-Dose Phase (one cycle of 4 weekly doses of CDX-1127). All patients with stable disease who do not experience a DLT or start alternate anti-cancer treatments may then be eligible for a Retreatment Phase (up to 4 additional cycles). Patients with confirmed partial response or complete response will be followed for response duration and may be eligible for additional cycles of treatment at the time of relapse/progression.~The dose of CDX-1127 given for the Dose Escalation phase will depend on the cohort each patient is assigned to, and will range between 0.1 and 10.0 mg/kg of CDX-1127.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDX-1127
Description: Patients will receive 4 weekly doses of CDX-1127 followed by an observation period. All patients with stable disease who do not experience a DLT or start alternate anti-cancer treatments may then be eligible for a Retreatment Phase (up to 4 additional cycles). Patients with confirmed partial response or complete response will be followed for response duration and may be eligible for additional cycles of treatment at the time of relapse/progression.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDX-1127
Description: Patients will receive four doses of CDX-1127 administered every three weeks followed by an observation period. All patients with stable disease who do not experience a DLT or start alternate anti-cancer treatments may then be eligible for a Retreatment Phase (up to 4 additional cycles). Patients with confirmed partial response or complete response will be followed for response duration and may be eligible for additional cycles of treatment at the time of relapse/progression.
Study: NCT03826186

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional (loss-of-resistance technique) thoracic epidural placement
Description: Thoracic epidurals will be administered using the traditional loss-of resistance technique.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CompuFlo thoracic epidural placement
Description: Pressure sensing technology to consistently and accurately identify the thoracic epidural space.
Study: NCT04797039

Intervention type: PROCEDURE
Intervention: MR guided cryoablation
Description: MR guided cryoablation of focal biopsy proven prostate cancer
Study: NCT04773366

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone+Cytarabine+vincristine+Mercaptopurine
Description: Group 1 Consolidation continuation treatment (W7\~W22) . Prednisone 40mg/m2 d1-5 q3w (w7,10,13,16,19,22); VCR 1.5/m2 iv d1 q3w (w7,10,13,16,19,22); Cytarabine 100mg/m2 iv/IH d1-4 q3w (w7,10,13,16,19,22); 6-MP 50mg/m2/d,po,qn
Study: NCT04358692

Intervention type: DEVICE
Group type: OTHER
Intervention: Aixplorer Mach30
Description: To measure myocardial stiffness by ShearWave elastography on not beating heart

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aixplorer Mach30
Description: To measure myocardial stiffness by ShearWave elastography on not beating heart
Study: NCT02975050

Intervention type: OTHER
Intervention: Location

Intervention type: OTHER
Intervention: Location
Study: NCT00972335

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: This drug will be dosed at 10 mg orally DAILY for the duration of the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: This drug will be given IV at 10 mg/kg on Days 1 and 15 of each 28-day treatment cycle for the duration of the study.
Study: NCT04427865

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prophylactic lactoferrin daily
Description: 200 mg oral lactoferrin daily
Study: NCT01764711

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cosyntropin administration
Description: After 30 minutes of rest in the seated position, participants will be given cosyntropin intravenously. Blood samples will be taken 30 minutes pre-drug administration, 30 minutes post and 60 minutes post drug administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cosyntropin administration
Description: After 30 minutes of rest in the seated position, participants will be given cosyntropin intravenously. Blood samples will be taken 30 minutes pre-drug administration, 30 minutes post and 60 minutes post drug administration.
Study: NCT01398007

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Camouflage syringe
Description: Dental anesthesia is administered using the camouflaged syringe.
Study: NCT02750670

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Type II anti-CD20 monoclonal antibody
Study: NCT02750670

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Antineoplastic agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Corticosteroid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Antineoplastic Agent
Study: NCT03796637

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ataluren
Description: Ataluren will be administered as per the dose and schedule specified in the arm.
Study: NCT01001117

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LensAR laser surgery
Description: Use of laser for cataract surgery

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Phaco-emulsification cataract surgery
Description: Phaco-emulsification cataract surgery
Study: NCT01499615

Intervention type: DEVICE
Intervention: cardiac monitor
Description: All children receive the same intervention which is the application of the 4 ekg electrodes
Study: NCT05099796

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transforaminal epidural steroid injection

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Caudal epidural steroid injection
Study: NCT00648362

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glimepiride Tablets 1 mg
Description: 1mg, single dose fasting

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amaryl® Tablets 1 mg
Description: 1mg, single dose fasting